Leishmaniose visceral no estado do Maranhäo, Brasil: a evoluçäo de uma epidemia

Costa, Jackson M. L; Viana, Graça Maria C; Saldanha, Ana Cristina R; Nascimento, Maria D. S. B; Alvim, Aymoré C; Burattini, Marcelo N; Silva, Antonio R. da.
Cad. saúde pública ; 11(2): 321-4, abr.-jun. 1995. ilus
Artigo em Português | LILACS | ID: lil-159036

Documentos relacionados

  1. Evaluating complete surface-associated and secretory proteome of Leishmania donovani for discovering novel vaccines and diagnostic targets.
  2. User friendliness, efficiency & spray quality of stirrup pumps versus hand compression pumps for indoor residual spraying.
  3. Potential of TLR agonist as an adjuvant in Leishmania vaccine against visceral leishmaniasis in BALB/c mice.
  4. Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future.
  5. Visceral leishmaniasis in new foci areas of Nepal: Sources and extent of infection.
  6. Leukoreduction as a control measure in transfusion transmission of visceral leishmaniasis.
  7. Factors associated with variation in insecticide quantity being used for indoor residual spraying (IRS) for visceral leishmaniasis (kala-azar) elimination in Bihar, India.
  8. LaSap vaccine: Immunotherapy and immunochemotherapy associated with allopurinol in dogs naturally infected with Leishmania infantum.
  9. A specific Leishmania infantum polyepitope vaccine triggers Th1-type immune response and protects against experimental visceral leishmaniasis.
  10. Impelling TLR9: Road to perspective vaccine for visceral leishmaniasis.